Latus Bio Announces Breakthrough in Gene Therapy with AAV-Ep+ Capsid
PHILADELPHIA, PA — Latus Bio, Inc. has unveiled groundbreaking research on a novel adeno-associated virus (AAV) capsid variant, AAV-Ep+, which shows significant promise for advancing gene therapy applications. Published in …
Latus Bio Announces Breakthrough in Gene Therapy with AAV-Ep+ Capsid Read More